In this study, we performed both in vitro and in vivo experiments to investigate how CHI3L1 contributes to disease pathogenesis, with the ultimate goal of clarifying its potential as a biomarker and therapeutic target in MS. The gene discussed is CHI3L1; the disease is myeloid sarcoma.